半乳甘露聚糖在曲霉菌酶免疫测定法中不表现出交叉反应性。
Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay.
作者信息
De Jesus Magdia, Hackett Emily, Durkin Michelle, Connolly Patricia, Casadevall Arturo, Petraitiene Ruta, Walsh Thomas J, Wheat L Joseph
机构信息
Albert Einstein College of Medicine, Bronx, NY 10461, USA.
出版信息
Clin Vaccine Immunol. 2007 May;14(5):624-7. doi: 10.1128/CVI.00368-06. Epub 2007 Mar 14.
Abstract
Given the recent report of a false-positive result in the Platelia Aspergillus enzyme immunoassay in a patient with cryptococcosis and in yeast extracts and purified galactoxylomannan of Cryptococcus neoformans, we evaluated culture extracts, purified polysaccharides, clinical specimens, and specimens from animals following experimental infection. Our results revealed no cross-reactions.
摘要
鉴于最近有报告称，在一名隐球菌病患者以及新型隐球菌的酵母提取物和纯化半乳甘露聚糖中，曲霉菌平板酶免疫测定出现假阳性结果，我们对培养提取物、纯化多糖、临床标本以及实验感染后动物的标本进行了评估。我们的结果显示没有交叉反应。
相似文献
1
Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay.
Clin Vaccine Immunol. 2007 May;14(5):624-7. doi: 10.1128/CVI.00368-06. Epub 2007 Mar 14.
2
Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan.
J Clin Microbiol. 2005 Jun;43(6):2929-31. doi: 10.1128/JCM.43.6.2929-2931.2005.
3
Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans.
Diagn Immunol. 1984;2(2):109-15.
4
An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
Res Immunol. 1990 Jan;141(1):33-42. doi: 10.1016/0923-2494(90)90099-k.
5
Clinical features and cause analysis of false positive results of Aspergillus galactomannan assay in pulmonary cryptococcosis patients.
Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):735-741. doi: 10.1007/s10096-019-03469-3. Epub 2019 Jan 25.
6
Cryptococcal glucoxylomannan does not exhibit cross-reactivity in the MVista Histoplasma antigen enzyme immunoassay.
Clin Vaccine Immunol. 2008 Feb;15(2):392-3. doi: 10.1128/CVI.00383-07. Epub 2007 Dec 12.
7
Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
Eukaryot Cell. 2009 Jan;8(1):96-103. doi: 10.1128/EC.00331-08. Epub 2008 Oct 24.
8
Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay.
Clin Vaccine Immunol. 2007 May;14(5):638-40. doi: 10.1128/CVI.00479-06. Epub 2007 Mar 7.
9
Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay.
Clin Vaccine Immunol. 2009 Jan;16(1):132-3. doi: 10.1128/CVI.00310-08. Epub 2008 Nov 19.
10
Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Cell Microbiol. 2008 Jun;10(6):1274-85. doi: 10.1111/j.1462-5822.2008.01125.x. Epub 2008 Jan 30.
引用本文的文献
1
Virulence factors released by extracellular vesicles from .
Front Cell Infect Microbiol. 2025 May 14;15:1572520. doi: 10.3389/fcimb.2025.1572520. eCollection 2025.
2
Clinical features and cause analysis of false positive results of Aspergillus galactomannan assay in pulmonary cryptococcosis patients.
Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):735-741. doi: 10.1007/s10096-019-03469-3. Epub 2019 Jan 25.
3
Galactofuranose antigens, a target for diagnosis of fungal infections in humans.
Future Sci OA. 2017 Jun 1;3(3):FSO199. doi: 10.4155/fsoa-2017-0030. eCollection 2017 Aug.
4
Evaluation of the Double Agar Gel Immunodiffusion Test and of the Enzyme-Linked Immunosorbent Assay in the Diagnosis and Follow-Up of Patients with Chronic Pulmonary Aspergillosis.
PLoS One. 2015 Aug 13;10(8):e0134841. doi: 10.1371/journal.pone.0134841. eCollection 2015.
5
Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable.
Eukaryot Cell. 2010 Jul;9(7):1018-28. doi: 10.1128/EC.00268-09. Epub 2010 Jan 8.
6
Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay.
Clin Vaccine Immunol. 2009 Jan;16(1):132-3. doi: 10.1128/CVI.00310-08. Epub 2008 Nov 19.
7
Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
Eukaryot Cell. 2009 Jan;8(1):96-103. doi: 10.1128/EC.00331-08. Epub 2008 Oct 24.
8
Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis.
Clin Vaccine Immunol. 2008 Jul;15(7):1095-105. doi: 10.1128/CVI.00068-08. Epub 2008 May 7.
9
Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1.
Med Mycol. 2008 Mar;46(2):153-62. doi: 10.1080/13693780701747182.
10
Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay.
Eur J Clin Microbiol Infect Dis. 2008 Apr;27(4):245-51. doi: 10.1007/s10096-007-0437-7. Epub 2008 Jan 9.
本文引用的文献
1
Galactomannan antigen detection in the diagnosis of invasive aspergillosis.
Expert Rev Mol Diagn. 2007 Jan;7(1):21-32. doi: 10.1586/14737159.7.1.21.
2
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.
J Biol Chem. 2006 Jan 27;281(4):1868-75. doi: 10.1074/jbc.M509465200. Epub 2005 Nov 8.
3
Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan.
J Clin Microbiol. 2005 Jun;43(6):2929-31. doi: 10.1128/JCM.43.6.2929-2931.2005.
4
A yeast under cover: the capsule of Cryptococcus neoformans.
Eukaryot Cell. 2003 Aug;2(4):655-63. doi: 10.1128/EC.2.4.655-663.2003.
5
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
J Infect Dis. 2003 Jun 15;187(12):1834-43. doi: 10.1086/375420. Epub 2003 Jun 4.
6
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
Infect Immun. 2001 Oct;69(10):6445-55. doi: 10.1128/IAI.69.10.6445-6455.2001.
7
Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67.
Carbohydr Res. 1998 Jan;306(1-2):315-30. doi: 10.1016/s0008-6215(97)10058-1.
8
9
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan.
J Clin Microbiol. 1997 Jan;35(1):257-60. doi: 10.1128/jcm.35.1.257-260.1997.
10
Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans.
Carbohydr Res. 1984 Feb 15;125(2):343-9. doi: 10.1016/0008-6215(84)85172-1.
Zotero 插件